Hypopara in the News
The latest research, clinical trials, treatment approvals, and advocacy news from around the hypoparathyroidism community — curated by Bari.
These articles are from external sources and are not written by Bari. They are shared for informational purposes to keep the hypopara community informed.
Management of Hypoparathyroidism: Italian Delphi Consensus Analysis
Journal of Endocrinological Investigation (Springer)
Twenty expert endocrinologists reached consensus on 41 management statements for hypoparathyroidism in Italy, identifying key gaps in care and supporting the role of palopegteriparatide in improving quality of life for patients with inadequately controlled disease.
Dynamic Parathyroid Physiology: A Rare Case of Hypoparathyroidism Progressing to Hyperparathyroidism With Full Recovery
Endocrine Practice (ScienceDirect)
A rare case report published in Endocrine Practice documenting a patient whose hypoparathyroidism spontaneously progressed to hyperparathyroidism with full parathyroid recovery. This case highlights the dynamic and sometimes reversible nature of parathyroid physiology, offering important insights for clinicians managing hypopara patients.
Subjective Health Status and Life Performance in Hypoparathyroidism: A 13-Country Survey
Frontiers in Endocrinology
A large 13-country patient and caregiver survey of 398 patients with inadequately controlled hypoparathyroidism reveals substantial disease burden, including significantly higher rates of renal insufficiency and reduced quality of life compared to population controls.
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting for Once-Weekly Canvuparatide
BioSpace
MBX Biosciences reports a successful End-of-Phase 2 FDA meeting for canvuparatide, a once-weekly PTH analog for hypoparathyroidism, and outlines the Phase 3 development plan — a major step toward a new treatment option.
At-home calcium testing device could have wide-ranging impact in health care
VCU News
VCU chemistry professor Xuewei Wang has created a portable, fingerstick-based at-home calcium monitoring device for hypopara patients — described as 'a glucose monitor, but for calcium.' Tralyte Health is commercializing the technology.
An at-home calcium tester is in development — and I'm celebrating!
Hypoparathyroidism News
Bari Vapnek celebrates the development of an at-home calcium testing device, reflecting on what this breakthrough means for the daily lives of hypoparathyroidism patients who rely on frequent calcium monitoring.
New Treatments for Hypoparathyroidism
Healthgrades
An overview of the latest treatment advances for hypoparathyroidism, including FDA-approved PTH replacement therapies and emerging options in clinical development.
Yorvipath Approved in Canada for Chronic Hypoparathyroidism
Yahoo Finance / Pendopharm
Pendopharm (a division of Pharmascience Inc.) announced Health Canada has granted market authorization for Yorvipath (palopegteriparatide) for the treatment of chronic hypoparathyroidism in Canadian adults — expanding access to PTH replacement therapy beyond the US and EU.
FDA approval of Palopegteriparatide as a promising orphan drug
PMC / National Library of Medicine
A review of the FDA approval of palopegteriparatide (TransCon PTH / Yorvipath) as an orphan drug for hypoparathyroidism, examining its clinical trial data, mechanism of action, and significance for patients.
A new trial for Allotransplantation: Parathyroid Allotransplant for Treatment of Hypoparathyroidism (PATTH)
Hypoparathyroidism Association
A new clinical trial is studying whether transplanting parathyroid tissue into the forearm can help hypoparathyroidism patients achieve sustained parathyroid hormone levels and reduce dependence on calcium and vitamin D supplements.
ESE announces Revised Clinical Practice Guideline for Treatment of Chronic Hypoparathyroidism in Adults
European Society of Endocrinology
The European Society of Endocrinology published updated clinical practice guidelines for treating chronic hypoparathyroidism in adults, reflecting new evidence and treatment options including PTH replacement therapy.
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide)
Ascendis Pharma
Long-term renal safety data from the TransCon PTH (palopegteriparatide) clinical program shared at Kidney Week 2025, demonstrating sustained kidney health outcomes over three years of treatment.
Could a New Pharmacological Treatment Provide Hope for Hypoparathyroidism Patients?
Endocrine News
In-depth follow-up on the FDA approval of palopegteriparatide for adults with hypoparathyroidism, exploring what this new pharmacological treatment means for patients and the future of hypopara care.
Encaleret Showed PTH-Independent Normalization of Blood and Urine Calcium in Phase 2 Study
BridgeBio Pharma
Phase 2 results show encaleret may help normalize blood and urine calcium in patients with chronic hypoparathyroidism without stimulating PTH — a first-in-class oral approach that works differently from PTH replacement.
Encaleret Developer Aims to Launch Registrational Clinical Trial for Chronic Hypoparathyroidism in 2026
Hypoparathyroidism News
BridgeBio Pharma announced plans to launch a registrational clinical trial for encaleret — an oral calcilytic targeting Autosomal Dominant Hypocalcemia Type 1 (ADH1) — in 2026, with the goal of supporting FDA approval for chronic hypoparathyroidism.
Enrollment begins in natural history study of hypoparathyroidism
Hypoparathyroidism News
Coverage of the SHINE natural history study at Columbia University, including Bari Vapnek's perspective on why understanding long-term complications is critical for informed treatment decisions.
"With new treatment options on the horizon, understanding the long-term complications of hypoparathyroidism can help both physicians and patients make informed decisions about their care pathways."— Bari Vapnek
The Hypoparathyroidism Association Announces Patient Enrollment in First Prospective Natural History Study
GlobeNewswire
The Hypoparathyroidism Association announced enrollment in the SHINE study (NCT05793853) at Columbia University, led by Dr. Mishaela Rubin and sponsored by the FDA's Office of Orphan Products Development. The first-of-its-kind natural history study will follow 94 adults for three years to understand long-term complications.
"This study is particularly important to the hypoparathyroidism community as it underscores the needed paradigm shift surrounding treatment and understanding of the condition."— Bari Vapnek
Spotlight: Tralyte Health
Tralyte Health is developing a portable, at-home calcium monitoring device — described as "a glucose monitor, but for calcium." Based on research by Dr. Xuewei Wang at Virginia Commonwealth University, the fingerstick-based system could deliver calcium readings in about 15 minutes. Clinical testing is planned for 2027.
Visit Tralyte HealthKnow of a News Article?
If you've seen a news article about hypoparathyroidism that should be featured here, let Bari know!
Send to Bari